Verona Pharma Stock Garners Investors' Attention After Successful COPD Trial

by Vandana Singh, Benzinga Editor
December 20, 2022 8:43 AM | 1 min read |
  • Verona Pharma plc VRNA has announced positive results of its Phase 3 ENHANCE-1 trial of nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
  • The ENHANCE-1 trial met its primary and key secondary endpoints demonstrating significant improvements in lung function, symptoms, and quality of life measures. 
  • In addition, ensifentrine substantially reduced the rate and risk of COPD exacerbations. 
  • Related: HC Wainwright Raises Price For This Lung Disease Stock On First Pivotal Readout.
  • Ensifentrine was well tolerated over 24 and 48 weeks.
  • Subjects receiving ensifentrine demonstrated a 36% reduction in the rate of moderate to severe COPD exacerbations over 24 weeks compared to those receiving placebo.
  • Pooled exacerbation data from ENHANCE-1 and ENHANCE-2, ensifentrine demonstrated a 40% reduction in the rate of moderate to severe COPD exacerbations over 24 weeks compared to those receiving placebo.
  • The company plans to submit a marketing application to the FDA in the first half of 2023.
  • Price Action: VRNA shares are up 34.84% at $18.15 during the premarket session on the last check Tuesday.
  • Photo Via Company
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefspremarket tradingwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!